Neurocrine Biosciences (NBIX) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Neurocrine Bio. (NBIX) PT Lowered to $105 at Cowen
February 6, 2019 7:54 AM ESTCowen analyst Phil Nadeau lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $105.00 (from $115.00) while maintaining a Outperform rating.
The analyst commented, "NBIX reported Q4 Ingrezza sales of $130.3MM, consistent with its January pre-announcement. Results from NBI-74788's Ph. IIa in CAH... More
